Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Should medical school deans have ties to pharma?

Deep Ramachandran, MD
Physician
February 5, 2013
Share
Tweet
Share

One of the first posts I wrote was a about how pharmaceutical reps provide lunch for physicians while presenting information about a medication that they are promoting.  The post, and others like it, have generated visceral reactions on the part of the public. A similar article to the one that I wrote prompted comments like “Get over yourself and buy your own lunch” and “I’m certainly glad that you are not my doctor.”

The opinions were so strong I was invited to speak on CNN about the topic. In particular, I was asked to speak about all the other extravagant things that physicians get from drug companies. I ultimately did not do the interview on account of me not having any experience with receiving any of the extravagant things they were talking about. It seemed to me that individual physicians receiving lunch was (excuse the pun) small potatoes compared to what happens behind closed doors in the halls of power. While upcoming rules will soon provide the public with a window into the value of goods provided to physicians by drug companies, they will provide little insight about where pharma has its greatest and most effective influence: behind the closed doors of those halls with thought leaders, opinion makers and legislators.

To that point, a story came to my attention recently that reminded me about that fact. The dean of Weill Cornell Medical College, a prestigious and highly regarded medical school, has apparently kept close financial ties with industry, as reported in the the college’s newspaper. The college’s Dean, a highly accomplished and awarded physician researcher, has retained positions with a major pharmaceutical company and a laboratory equipment company. In these roles last year she reportedly received about $260,000 from one of the companies and about $277,000 from the other last year. The Cornell Daily Sun also reports that she has apparently received millions of dollars in compensation from both companies over the years as well as more than a million dollars worth of shares and stock options in the companies.

As dean of a prestigious medical college, she must undoubtedly understand that she has the ability to influence the behaviors of thousands of future physicians, and the  power to lead by example. I find it appallingly hypocritical that, while the dean sits on the board of these companies, she is training future physicians who will be discouraged from receiving anything of value from the pharmaceutical industry.

To get a better understanding of the depth of this double standard, take a look at the pharmaceutical vendor policy of the medical college’s affiliated hospital. In an effort to control costs, they have significantly restricted the activities and access that pharmaceutical representatives have in their facility. This is fairly common practice among hospitals, as is the practice of restricting inpatient medications to cheaper generics whenever possible. Hospitals know that the presence of pharma reps increases costs by encouraging physicians to use the more expensive medications. Hospitals thus try to reduce the influence of the reps on physicians both by  removing the expensive alternatives from the hospital pharmacy, and by limiting access to pharma reps.

Like many other hospitals, reps here need to be credentialed and registered by the hospital before being allowed access. They must enter the facility through specific entrances designated for reps, and they may enter by appointment only. Furthermore, the hospital’s policy explicitly states that reps are not allowed to meet with medical students on hospital property. Nor do they allow free drug samples to be distributed by pharmaceutical representatives.

By now it should be exceedingly self evident why telling your students on one hand not to speak with pharmaceutical reps, and on the other taking millions of dollars from the same company would be hypocritical. That we should ask more of our medical educators and health care leaders is also self evident. And I could say a lot more, too. I could say how inappropriate this is, and ask that all medical college deans take a pledge to no longer take money from industry. But instead I would like to defer to a simple message which summed up what most people felt about a recent article on drug rep lunches that I think fairly and accurately sums up this situation as well. The comment, directed at the medical community, said simply and emphatically, “Who’s money do you think you’re spending? IT IS IMPROPER BEHAVIOR!”

Deep Ramachandran is a pulmonary and critical care physician who blogs at CaduceusBlog.  He can be reached on Twitter @Caduceusblogger.

Prev

What is observation care? Clearing up common misperceptions

February 4, 2013 Kevin 3
…
Next

Why doctors and nurses should be required to have flu shots

February 5, 2013 Kevin 35
…

Tagged as: Medical school, Medications

Post navigation

< Previous Post
What is observation care? Clearing up common misperceptions
Next Post >
Why doctors and nurses should be required to have flu shots

ADVERTISEMENT

More by Deep Ramachandran, MD

  • We can’t build our way out of the ventilator shortage. But there is a solution.

    Deep Ramachandran, MD
  • When someone is not dead but not alive

    Deep Ramachandran, MD
  • The hurricane in Puerto Rico is leading a shortage in saline bags

    Deep Ramachandran, MD

More in Physician

  • Guilty until proven innocent? My experience with a state medical board.

    Jeffrey Hatef, Jr., MD
  • How to balance clinical duties with building a startup

    Arlen Meyers, MD, MBA
  • When life makes you depend on Depends

    Francisco M. Torres, MD
  • Implementing value-based telehealth pain management and substance misuse therapy service

    Olumuyiwa Bamgbade, MD
  • How an insider advocate can save a loved one

    Chrissie Ott, MD
  • A powerful story of addiction, strength, and redemption

    Ryan McCarthy, MD
  • Most Popular

  • Past Week

    • How hospitals can prepare for CMS’s new patient safety rule

      Kim Adelman, PhD | Conditions
    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why leadership training in medicine needs to start with self-awareness

      Amelie Oshikoya, MD, MHA | Education
    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
    • Why clinicians must lead health care tech innovation

      Kimberly Smith, RN | Tech
    • The truth about sun exposure: What dermatologists want you to know

      Shafat Hassan, MD, PhD, MPH | Conditions
    • Learning medicine in the age of AI: Why future doctors need digital fluency

      Kelly D. França | Education
    • How a South Asian nurse challenged stereotypes in health care

      Viksit Bali, RN | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 8 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • How hospitals can prepare for CMS’s new patient safety rule

      Kim Adelman, PhD | Conditions
    • How a doctor defied a hurricane to save a life

      Dharam Persaud-Sharma, MD, PhD | Physician
    • Why primary care needs better dermatology training

      Alex Siauw | Conditions
    • Guilty until proven innocent? My experience with a state medical board.

      Jeffrey Hatef, Jr., MD | Physician
    • Why physician strikes are a form of hospice

      Patrick Hudson, MD | Physician
    • Why medical notes have become billing scripts instead of patient stories

      Sriman Swarup, MD, MBA | Tech
  • Past 6 Months

    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • COVID-19 was real: a doctor’s frontline account

      Randall S. Fong, MD | Conditions
    • Why primary care doctors are drowning in debt despite saving lives

      John Wei, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Confessions of a lipidologist in recovery: the infection we’ve ignored for 40 years

      Larry Kaskel, MD | Conditions
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • Why leadership training in medicine needs to start with self-awareness

      Amelie Oshikoya, MD, MHA | Education
    • Federal shakeup of vaccine policy and the battle for public trust [PODCAST]

      American College of Physicians & The Podcast by KevinMD | Podcast
    • Why clinicians must lead health care tech innovation

      Kimberly Smith, RN | Tech
    • The truth about sun exposure: What dermatologists want you to know

      Shafat Hassan, MD, PhD, MPH | Conditions
    • Learning medicine in the age of AI: Why future doctors need digital fluency

      Kelly D. França | Education
    • How a South Asian nurse challenged stereotypes in health care

      Viksit Bali, RN | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Should medical school deans have ties to pharma?
8 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...